Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Omeros

Omeros
1994 FOUNDED
PUBLIC STATUS
201-300 EMPLOYEES
OMER STOCK SYMBOL
2 INVESTMENTS
$16.70 SHARE PRICE (As of Monday Closing)
Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 201 Elliott Avenue West
  • Seattle, WA 98119
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Omeros’s full profile, request a free trial.

Omeros Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$10.30 - $27.00 $786M $16.04 -$2.61 710K 49M

Omeros Financials Summary

In Thousands,
USD
TTM
31-Dec-2018
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 623,063 623,063 929,046 448,764
Revenue 29,868 29,868 64,826 41,617
EBITDA (122,472) (122,472) (41,900) (58,626)
Net Income (126,757) (126,757) (53,481) (66,745)
Total Assets 95,936 95,936 116,328 67,278
Total Debt 151,448 151,448 84,607 79,710
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Omeros Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Omeros‘s full profile, request access.

Request full access to PitchBook

Omeros Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 (0000 000 23-Nov-2010 000000000000000000 000.00 Biotechnology 0000000 000000000 00
Nura 07-Sep-2006 Merger/Acquisition 00000 Drug Discovery 0000000 000000000 00
To view this company’s complete investment and acquisition history, request access »

Omeros Executive Team (14)

Name Title Board
Seat
Contact
Info
Gregory Demopulos MD Founder, President, Chief Executive Officer & Chairman
Richard Klein Chief Financial Officer
Michael Jacobsen Chief Accounting Officer, Treasurer & Vice President, Finance
George Gaitanaris Ph.D Chief Scientific Officer & Vice President, Science
Leonard Blum Chief Business and Commercial Officer

2 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Omeros Board Members (7)

Name Representing Role Since Contact
Info
000000 000000 Omeros Chairman of Audit Committee 000 0000
00000 0000 00.0 Self Board Member 000 0000
00000 000000000 00 Omeros Board Member 000 0000
00000 0000 00 Self Board Member 000 0000
000 000000 Omeros Board Member & Member of Audit Committees 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »